-
1
-
-
53049101877
-
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
-
Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, and Webber J (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135:1176-1184.
-
(2008)
Gastroenterology
, vol.135
, pp. 1176-1184
-
-
Aithal, G.P.1
Thomas, J.A.2
Kaye, P.V.3
Lawson, A.4
Ryder, S.D.5
Spendlove, I.6
Austin, A.S.7
Freeman, J.G.8
Morgan, L.9
Webber, J.10
-
2
-
-
85041823681
-
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
-
Angelico F, Burattin M, Alessandri C, Del Ben M, and Lirussi F (2007) Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev (1):CD005166.
-
(2007)
Cochrane Database Syst Rev (1)
, pp. CD005166
-
-
Angelico, F.1
Burattin, M.2
Alessandri, C.3
Del Ben, M.4
Lirussi, F.5
-
3
-
-
0037129380
-
Nonalcoholic fatty liver disease
-
Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231.
-
(2002)
N Engl J Med
, vol.346
, pp. 1221-1231
-
-
Angulo, P.1
-
4
-
-
33750722500
-
A temporal study on the histopathological, biochemical and molecular responses of CCl(4)-induced hepatotoxicity in Cyp2e1-null mice
-
Avasarala S, Yang L, Sun Y, Leung AW, Chan WY, Cheung WT, and Lee SS (2006) A temporal study on the histopathological, biochemical and molecular responses of CCl(4)-induced hepatotoxicity in Cyp2e1-null mice. Toxicology 228:310-322.
-
(2006)
Toxicology
, vol.228
, pp. 310-322
-
-
Avasarala, S.1
Yang, L.2
Sun, Y.3
Leung, A.W.4
Chan, W.Y.5
Cheung, W.T.6
Lee, S.S.7
-
6
-
-
33751545838
-
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
-
Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, and Pulcini J, et al. (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297-2307.
-
(2006)
N Engl J Med
, vol.355
, pp. 2297-2307
-
-
Belfort, R.1
Harrison, S.A.2
Brown, K.3
Darland, C.4
Finch, J.5
Hardies, J.6
Balas, B.7
Gastaldelli, A.8
Tio, F.9
Pulcini, J.10
-
7
-
-
33745125943
-
Spectrophotometric analysis of human CYP2E1-catalyzed p-nitrophenol hydroxylation
-
Chang TK, Crespi CL, and Waxman DJ (2006) Spectrophotometric analysis of human CYP2E1-catalyzed p-nitrophenol hydroxylation. Methods Mol Biol 320:127-131.
-
(2006)
Methods Mol Biol
, vol.320
, pp. 127-131
-
-
Chang, T.K.1
Crespi, C.L.2
Waxman, D.J.3
-
8
-
-
33747517955
-
The epidemiology of nonalcoholic fatty liver disease in adults
-
Clark JM (2006) The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 40 (Suppl 1):S5-S10.
-
(2006)
J Clin Gastroenterol
, vol.40
, pp. S5-S10
-
-
Clark, J.M.1
-
9
-
-
77957961658
-
Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis
-
Cole LK, Jacobs RL, and Vance DE (2010) Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology 52: 1258-1265.
-
(2010)
Hepatology
, vol.52
, pp. 1258-1265
-
-
Cole, L.K.1
Jacobs, R.L.2
Vance, D.E.3
-
10
-
-
0037075831
-
Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A(2) based on a 1,3-disubstituted propan-2-one skeleton
-
Connolly S, Bennion C, Botterell S, Croshaw PJ, Hallam C, Hardy K, Hartopp P, Jackson CG, King SJ, and Lawrence L, et al. (2002) Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A(2) based on a 1,3-disubstituted propan-2-one skeleton. J Med Chem 45:1348-1362.
-
(2002)
J Med Chem
, vol.45
, pp. 1348-1362
-
-
Connolly, S.1
Bennion, C.2
Botterell, S.3
Croshaw, P.J.4
Hallam, C.5
Hardy, K.6
Hartopp, P.7
Jackson, C.G.8
King, S.J.9
Lawrence, L.10
-
11
-
-
1642285767
-
Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis
-
Czaja AJ and Carpenter HA (2004) Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 40:646-652.
-
(2004)
J Hepatol
, vol.40
, pp. 646-652
-
-
Czaja, A.J.1
Carpenter, H.A.2
-
12
-
-
33750038908
-
Effects of pyrrophenone, an inhibitor of group IVA phospholipase A2, on eicosanoid and PAF biosynthesis in human neutrophils
-
Flamand N, Picard S, Lemieux L, Pouliot M, Bourgoin SG, and Borgeat P (2006) Effects of pyrrophenone, an inhibitor of group IVA phospholipase A2, on eicosanoid and PAF biosynthesis in human neutrophils. Br J Pharmacol 149:385-392.
-
(2006)
Br J Pharmacol
, vol.149
, pp. 385-392
-
-
Flamand, N.1
Picard, S.2
Lemieux, L.3
Pouliot, M.4
Bourgoin, S.G.5
Borgeat, P.6
-
13
-
-
70449158340
-
A simple method for the isolation and purification of total lipides from animal tissues
-
Folch J, Lees M, and Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497-509.
-
(1957)
J Biol Chem
, vol.226
, pp. 497-509
-
-
Folch, J.1
Lees, M.2
Sloane Stanley, G.H.3
-
14
-
-
41649107806
-
1-(2-Carboxyindol-5-yloxy) propan-2-ones as inhibitors of human cytosolic phospholipase A2a: Synthesis, biological activity, metabolic stability, and solubility
-
Fritsche A, Elfringhoff AS, Fabian J, and Lehr M (2008) 1-(2-Carboxyindol-5-yloxy) propan-2-ones as inhibitors of human cytosolic phospholipase A2a: synthesis, biological activity, metabolic stability, and solubility. Bioorg Med Chem 16: 3489-3500.
-
(2008)
Bioorg Med Chem
, vol.16
, pp. 3489-3500
-
-
Fritsche, A.1
Elfringhoff, A.S.2
Fabian, J.3
Lehr, M.4
-
15
-
-
33845593130
-
Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver
-
Gudbrandsen OA, Rost TH, and Berge RK (2006) Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. J Lipid Res 47: 2223-2232.
-
(2006)
J Lipid Res
, vol.47
, pp. 2223-2232
-
-
Gudbrandsen, O.A.1
Rost, T.H.2
Berge, R.K.3
-
16
-
-
33947111963
-
1-(5-Carboxy-and 5-carbamoylindol-1-yl)propan-2-ones as inhibitors of human cytosolic phospholipase A2a: Bioisosteric replacement of the carboxylic acid and carboxamide moiety
-
Hess M, Schulze Elfringhoff A, and Lehr M (2007) 1-(5-Carboxy-and 5-carbamoylindol-1-yl)propan-2-ones as inhibitors of human cytosolic phospholipase A2a: bioisosteric replacement of the carboxylic acid and carboxamide moiety. Bioorg Med Chem 15:2883-2891.
-
(2007)
Bioorg Med Chem
, vol.15
, pp. 2883-2891
-
-
Hess, M.1
Schulze Elfringhoff, A.2
Lehr, M.3
-
17
-
-
77949522423
-
Alleviation of high-fat diet-induced fatty liver damage in group IVA phospholipase A2-knockout mice
-
Ii H, Yokoyama N, Yoshida S, Tsutsumi K, Hatakeyama S, Sato T, Ishihara K, and Akiba S (2009) Alleviation of high-fat diet-induced fatty liver damage in group IVA phospholipase A2-knockout mice. PLoS One 4:e8089.
-
(2009)
PLoS One
, vol.4
-
-
Ii, H.1
Yokoyama, N.2
Yoshida, S.3
Tsutsumi, K.4
Hatakeyama, S.5
Sato, T.6
Ishihara, K.7
Akiba, S.8
-
18
-
-
84868091753
-
Group IVA phospholipase A2 participates in the progression of hepatic fibrosis
-
Ishihara K, Miyazaki A, Nabe T, Fushimi H, Iriyama N, Kanai S, Sato T, Uozumi N, Shimizu T, and Akiba S (2012) Group IVA phospholipase A2 participates in the progression of hepatic fibrosis. FASEB J 26:4111-4121.
-
(2012)
FASEB J
, vol.26
, pp. 4111-4121
-
-
Ishihara, K.1
Miyazaki, A.2
Nabe, T.3
Fushimi, H.4
Iriyama, N.5
Kanai, S.6
Sato, T.7
Uozumi, N.8
Shimizu, T.9
Akiba, S.10
-
19
-
-
0026556949
-
Free fatty acid transfer from rat liver fatty acid-binding protein to phospholipid vesicles
-
Kim HK and Storch J (1992) Free fatty acid transfer from rat liver fatty acid-binding protein to phospholipid vesicles. Effect of ligand and solution properties. J Biol Chem 267:77-82.
-
(1992)
Effect of Ligand and Solution Properties. J Biol Chem
, vol.267
, pp. 77-82
-
-
Kim, H.K.1
Storch, J.2
-
20
-
-
33750964517
-
Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s
-
Kita Y, Ohto T, Uozumi N, and Shimizu T (2006) Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. Biochim Biophys Acta 1761: 1317-1322.
-
(2006)
Biochim Biophys Acta
, vol.1761
, pp. 1317-1322
-
-
Kita, Y.1
Ohto, T.2
Uozumi, N.3
Shimizu, T.4
-
21
-
-
20044374023
-
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
-
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, and Unalp-Arida A, et al.; Nonalcoholic Steatohepatitis Clinical Research Network (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321.
-
(2005)
Hepatology
, vol.41
, pp. 1313-1321
-
-
Nonalcoholic Steatohepatitis Clinical Research Network1
Kleiner, D.E.2
Brunt, E.M.3
Van Natta, M.4
Behling, C.5
Contos, M.J.6
Cummings, O.W.7
Ferrell, L.D.8
Liu, Y.C.9
Torbenson, M.S.10
Unalp-Arida, A.11
-
22
-
-
0037019263
-
Novel 2-oxoamide inhibitors of human group IVA phospholipase A(2)
-
Kokotos G, Kotsovolou S, Six DA, Constantinou-Kokotou V, Beltzner CC, and Dennis EA (2002) Novel 2-oxoamide inhibitors of human group IVA phospholipase A(2). J Med Chem 45:2891-2893.
-
(2002)
J Med Chem
, vol.45
, pp. 2891-2893
-
-
Kokotos, G.1
Kotsovolou, S.2
Six, D.A.3
Constantinou-Kokotou, V.4
Beltzner, C.C.5
Dennis, E.A.6
-
23
-
-
3042599028
-
Inhibition of group IVA cytosolic phospholipase A2 by novel 2-oxoamides in vitro, in cells, and in vivo
-
Kokotos G, Six DA, Loukas V, Smith T, Constantinou-Kokotou V, Hadjipavlou-Litina D, Kotsovolou S, Chiou A, Beltzner CC, and Dennis EA (2004) Inhibition of group IVA cytosolic phospholipase A2 by novel 2-oxoamides in vitro, in cells, and in vivo. J Med Chem 47:3615-3628.
-
(2004)
J Med Chem
, vol.47
, pp. 3615-3628
-
-
Kokotos, G.1
Six, D.A.2
Loukas, V.3
Smith, T.4
Constantinou-Kokotou, V.5
Hadjipavlou-Litina, D.6
Kotsovolou, S.7
Chiou, A.8
Beltzner, C.C.9
Dennis, E.A.10
-
24
-
-
0035742752
-
Decreasing fibrogenesis: An immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B
-
Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burchardt E, Schoonhoven R, Brenner DA, and Fried MW (2001) Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 35:749-755.
-
(2001)
J Hepatol
, vol.35
, pp. 749-755
-
-
Kweon, Y.O.1
Goodman, Z.D.2
Dienstag, J.L.3
Schiff, E.R.4
Brown, N.A.5
Burchardt, E.6
Schoonhoven, R.7
Brenner, D.A.8
Fried, M.W.9
-
25
-
-
34648832073
-
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials
-
Lago RM, Singh PP, and Nesto RW (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370:1129-1136.
-
(2007)
Lancet
, vol.370
, pp. 1129-1136
-
-
Lago, R.M.1
Singh, P.P.2
Nesto, R.W.3
-
26
-
-
77958113232
-
Bone loss in diabetes: Use of antidiabetic thiazolidinediones and secondary osteoporosis
-
Lecka-Czernik B (2010) Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 8:178-184.
-
(2010)
Curr Osteoporos Rep
, vol.8
, pp. 178-184
-
-
Lecka-Czernik, B.1
-
27
-
-
33947732957
-
Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2a
-
Lee KL, Foley MA, Chen L, Behnke ML, Lovering FE, Kirincich SJ, Wang W, Shim J, Tam S, and Shen MW, et al. (2007) Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2a. J Med Chem 50:1380-1400.
-
(2007)
J Med Chem
, vol.50
, pp. 1380-1400
-
-
Lee, K.L.1
Foley, M.A.2
Chen, L.3
Behnke, M.L.4
Lovering, F.E.5
Kirincich, S.J.6
Wang, W.7
Shim, J.8
Tam, S.9
Shen, M.W.10
-
28
-
-
78650509559
-
Gene expression profiling of murine hepatic steatosis induced by tamoxifen
-
Lee MH, Kim JW, Kim JH, Kang KS, Kong G, and Lee MO (2010) Gene expression profiling of murine hepatic steatosis induced by tamoxifen. Toxicol Lett 199: 416-424.
-
(2010)
Toxicol Lett
, vol.199
, pp. 416-424
-
-
Lee, M.H.1
Kim, J.W.2
Kim, J.H.3
Kang, K.S.4
Kong, G.5
Lee, M.O.6
-
29
-
-
21744460524
-
Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis
-
Lelliott CJ, Lápez M, Curtis RK, Parker N, Laudes M, Yeo G, Jimenez-Liñan M, Grosse J, Saha AK, and Wiggins D, et al. (2005) Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J 19:1108-1119.
-
(2005)
FASEB J
, vol.19
, pp. 1108-1119
-
-
Lelliott, C.J.1
Lápez, M.2
Curtis, R.K.3
Parker, N.4
Laudes, M.5
Yeo, G.6
Jimenez-Liñan, M.7
Grosse, J.8
Saha, A.K.9
Wiggins, D.10
-
30
-
-
81355149613
-
Cytosolic phospholipase A(2)a protects against Fas-but not LPS-induced liver injury
-
Li G, Chen W, Han C, and Wu T (2011) Cytosolic phospholipase A(2)a protects against Fas-but not LPS-induced liver injury. J Hepatol 55:1281-1290.
-
(2011)
J Hepatol
, vol.55
, pp. 1281-1290
-
-
Li, G.1
Chen, W.2
Han, C.3
Wu, T.4
-
31
-
-
34249053143
-
Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis
-
Lirussi F, Azzalini L, Orando S, Orlando R, and Angelico F (2007) Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev (1):CD004996.
-
(2007)
Cochrane Database Syst Rev (1)
, pp. CD004996
-
-
Lirussi, F.1
Azzalini, L.2
Orando, S.3
Orlando, R.4
Angelico, F.5
-
32
-
-
33646146486
-
Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A2a
-
Ludwig J, Bovens S, Brauch C, Elfringhoff AS, and Lehr M (2006) Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A2a. J Med Chem 49:2611-2620.
-
(2006)
J Med Chem
, vol.49
, pp. 2611-2620
-
-
Ludwig, J.1
Bovens, S.2
Brauch, C.3
Elfringhoff, A.S.4
Lehr, M.5
-
33
-
-
0036154816
-
NASH: From liver diseases to metabolic disorders and back to clinical hepatology
-
Marchesini G and Forlani G (2002) NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 35:497-499.
-
(2002)
Hepatology
, vol.35
, pp. 497-499
-
-
Marchesini, G.1
Forlani, G.2
-
34
-
-
55849127739
-
Obesity-associated liver disease
-
Marchesini G, Moscatiello S, Di Domizio S, and Forlani G (2008) Obesity-associated liver disease. J Clin Endocrinol Metab 93(11, Suppl 1)S74-S80.
-
(2008)
J Clin Endocrinol Metab
, vol.93
, Issue.11
, pp. S74-S80
-
-
Marchesini, G.1
Moscatiello, S.2
Di Domizio, S.3
Forlani, G.4
-
35
-
-
0031043030
-
The mitochondrial carnitine palmitoyltransferase system. from concept to molecular analysis
-
McGarry JD and Brown NF (1997) The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 244:1-14.
-
(1997)
Eur J Biochem
, vol.244
, pp. 1-14
-
-
McGarry, J.D.1
Brown, N.F.2
-
36
-
-
30444460888
-
Inhibition of cytosolic phospholipase A2a: Hit to lead optimization
-
McKew JC, Foley MA, Thakker P, Behnke ML, Lovering FE, Sum FW, Tam S, Wu K, Shen MW, and Zhang W, et al. (2006) Inhibition of cytosolic phospholipase A2a: hit to lead optimization. J Med Chem 49:135-158.
-
(2006)
J Med Chem
, vol.49
, pp. 135-158
-
-
McKew, J.C.1
Foley, M.A.2
Thakker, P.3
Behnke, M.L.4
Lovering, F.E.5
Sum, F.W.6
Tam, S.7
Wu, K.8
Shen, M.W.9
Zhang, W.10
-
37
-
-
45749141743
-
Indole cytosolic phospholipase A2 a inhibitors: Discovery and in vitro and in vivo characterization of 4-3-[5-chloro-2-(2-[(3,4-dichlorobenzyl)sulfonyl]aminoethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propylbenzoic acid, efipladib
-
McKew JC, Lee KL, Shen MW, Thakker P, Foley MA, Behnke ML, Hu B, Sum FW, Tam S, and Hu Y, et al. (2008) Indole cytosolic phospholipase A2 a inhibitors: discovery and in vitro and in vivo characterization of 4-3-[5-chloro-2-(2-[(3,4-dichlorobenzyl)sulfonyl]aminoethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propylbenzoic acid, efipladib. J Med Chem51:3388-3413.
-
(2008)
J Med Chem
, vol.51
, pp. 3388-3413
-
-
McKew, J.C.1
Lee, K.L.2
Shen, M.W.3
Thakker, P.4
Foley, M.A.5
Behnke, M.L.6
Hu, B.7
Sum, F.W.8
Tam, S.9
Hu, Y.10
-
38
-
-
0344064798
-
Structure-activity relationships of indole cytosolic phospholipase A(2)a inhibitors: Substrate mimetics
-
McKew JC, Lovering F, Clark JD, Bemis J, Xiang Y, Shen M, Zhang W, Alvarez JC, and Joseph-McCarthy D (2003) Structure-activity relationships of indole cytosolic phospholipase A(2)a inhibitors: substrate mimetics. Bioorg Med Chem Lett 13: 4501-4504.
-
(2003)
Bioorg Med Chem Lett
, vol.13
, pp. 4501-4504
-
-
McKew, J.C.1
Lovering, F.2
Clark, J.D.3
Bemis, J.4
Xiang, Y.5
Shen, M.6
Zhang, W.7
Alvarez, J.C.8
Joseph-McCarthy, D.9
-
39
-
-
77954239704
-
A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease
-
Musso G, Gambino R, Cassader M, and Pagano G (2010) A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52: 79-104.
-
(2010)
Hepatology
, vol.52
, pp. 79-104
-
-
Musso, G.1
Gambino, R.2
Cassader, M.3
Pagano, G.4
-
40
-
-
0019948222
-
Specificity of a phenobarbital-induced cytochrome P-450 for metabolism of carbon tetrachloride to the trichloromethyl radical
-
Noguchi T, Fong KL, Lai EK, Alexander SS, King MM, Olson L, Poyer JL, and McCay PB (1982) Specificity of a phenobarbital-induced cytochrome P-450 for metabolism of carbon tetrachloride to the trichloromethyl radical. Biochem Pharmacol 31: 615-624.
-
(1982)
Biochem Pharmacol
, vol.31
, pp. 615-624
-
-
Noguchi, T.1
Fong, K.L.2
Lai, E.K.3
Alexander, S.S.4
King, M.M.5
Olson, L.6
Poyer, J.L.7
McCay, P.B.8
-
41
-
-
0036566182
-
Characterization of a novel inhibitor of cytosolic phospholipase A2a, pyrrophenone
-
Ono T, Yamada K, Chikazawa Y, Ueno M, Nakamoto S, Okuno T, and Seno K (2002) Characterization of a novel inhibitor of cytosolic phospholipase A2a, pyrrophenone. Biochem J 363:727-735.
-
(2002)
Biochem J
, vol.363
, pp. 727-735
-
-
Ono, T.1
Yamada, K.2
Chikazawa, Y.3
Ueno, M.4
Nakamoto, S.5
Okuno, T.6
Seno, K.7
-
43
-
-
0037105253
-
Rosmarinic acid, a major polyphenolic component of Perilla frutescens, reduces lipopolysaccharide (LPS)-induced liver injury in D-galactosamine (D-GalN)-sensitized mice
-
Osakabe N, Yasuda A, Natsume M, Sanbongi C, Kato Y, Osawa T, and Yoshikawa T (2002) Rosmarinic acid, a major polyphenolic component of Perilla frutescens, reduces lipopolysaccharide (LPS)-induced liver injury in D-galactosamine (D-GalN)-sensitized mice. Free Radic Biol Med 33:798-806.
-
(2002)
Free Radic Biol Med
, vol.33
, pp. 798-806
-
-
Osakabe, N.1
Yasuda, A.2
Natsume, M.3
Sanbongi, C.4
Kato, Y.5
Osawa, T.6
Yoshikawa, T.7
-
44
-
-
80051975559
-
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting
-
Piccinni C, Motola D, Marchesini G, and Poluzzi E (2011) Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 34:1369-1371.
-
(2011)
Diabetes Care
, vol.34
, pp. 1369-1371
-
-
Piccinni, C.1
Motola, D.2
Marchesini, G.3
Poluzzi, E.4
-
45
-
-
4444289142
-
Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes
-
Safadi R, Ohta M, Alvarez CE, Fiel MI, Bansal M, Mehal WZ, and Friedman SL (2004) Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 127:870-882.
-
(2004)
Gastroenterology
, vol.127
, pp. 870-882
-
-
Safadi, R.1
Ohta, M.2
Alvarez, C.E.3
Fiel, M.I.4
Bansal, M.5
Mehal, W.Z.6
Friedman, S.L.7
-
46
-
-
77951874018
-
Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis
-
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, and Unalp A, et al.; NASH CRN (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:1675-1685.
-
(2010)
N Engl J Med
, vol.362
, pp. 1675-1685
-
-
NASH C.R.N.1
Sanyal, A.J.2
Chalasani, N.3
Kowdley, K.V.4
McCullough, A.5
Diehl, A.M.6
Bass, N.M.7
Neuschwander-Tetri, B.A.8
Lavine, J.E.9
Tonascia, J.10
Unalp, A.11
-
47
-
-
0034704801
-
Pyrrolidine inhibitors of human cytosolic phospholipase A(2)
-
Seno K, Okuno T, Nishi K, Murakami Y, Watanabe F, Matsuura T, Wada M, Fujii Y, Yamada M, and Ogawa T, et al. (2000) Pyrrolidine inhibitors of human cytosolic phospholipase A(2). J Med Chem 43:1041-1044.
-
(2000)
J Med Chem
, vol.43
, pp. 1041-1044
-
-
Seno, K.1
Okuno, T.2
Nishi, K.3
Murakami, Y.4
Watanabe, F.5
Matsuura, T.6
Wada, M.7
Fujii, Y.8
Yamada, M.9
Ogawa, T.10
-
48
-
-
0035952312
-
Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: Synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'
-
Seno K, Okuno T, Nishi K, Murakami Y, Yamada K, Nakamoto S, and Ono T (2001) Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'. Bioorg Med Chem Lett 11:587-590.
-
(2001)
Bioorg Med Chem Lett
, vol.11
, pp. 587-590
-
-
Seno, K.1
Okuno, T.2
Nishi, K.3
Murakami, Y.4
Yamada, K.5
Nakamoto, S.6
Ono, T.7
-
49
-
-
34548125295
-
Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group v secreted phospholipase A2
-
Six DA, Barbayianni E, Loukas V, Constantinou-Kokotou V, Hadjipavlou-Litina D, Stephens D, Wong AC, Magrioti V, Moutevelis-Minakakis P, and Baker SF, et al. (2007) Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group V secreted phospholipase A2. J Med Chem 50: 4222-4235.
-
(2007)
J Med Chem
, vol.50
, pp. 4222-4235
-
-
Six, D.A.1
Barbayianni, E.2
Loukas, V.3
Constantinou-Kokotou, V.4
Hadjipavlou-Litina, D.5
Stephens, D.6
Wong, A.C.7
Magrioti, V.8
Moutevelis-Minakakis, P.9
Baker, S.F.10
-
50
-
-
33646461525
-
Differential inhibition of group IVA and group VIA phospholipases A2 by 2-oxoamides
-
Stephens D, Barbayianni E, Constantinou-Kokotou V, Peristeraki A, Six DA, Cooper J, Harkewicz R, Deems RA, Dennis EA, and Kokotos G (2006) Differential inhibition of group IVA and group VIA phospholipases A2 by 2-oxoamides. J Med Chem 49:2821-2828.
-
(2006)
J Med Chem
, vol.49
, pp. 2821-2828
-
-
Stephens, D.1
Barbayianni, E.2
Constantinou-Kokotou, V.3
Peristeraki, A.4
Six, D.A.5
Cooper, J.6
Harkewicz, R.7
Deems, R.A.8
Dennis, E.A.9
Kokotos, G.10
-
51
-
-
84899764290
-
Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)
-
Takaki A, Kawai D, and Yamamoto K (2014) Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci 15: 7352-7379.
-
(2014)
Int J Mol Sci
, vol.15
, pp. 7352-7379
-
-
Takaki, A.1
Kawai, D.2
Yamamoto, K.3
-
52
-
-
77952565420
-
The role of cytokines in non-alcoholic fatty liver disease
-
Tilg H (2010) The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 28: 179-185.
-
(2010)
Dig Dis
, vol.28
, pp. 179-185
-
-
Tilg, H.1
-
53
-
-
78049522194
-
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
-
Tilg H and Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52:1836-1846.
-
(2010)
Hepatology
, vol.52
, pp. 1836-1846
-
-
Tilg, H.1
Moschen, A.R.2
-
54
-
-
1942470397
-
Review article: Current management of alcoholic liver disease
-
Tome S and Lucey MR (2004) Review article: current management of alcoholic liver disease. Aliment Pharmacol Ther 19:707-714.
-
(2004)
Aliment Pharmacol Ther
, vol.19
, pp. 707-714
-
-
Tome, S.1
Lucey, M.R.2
-
55
-
-
84921457246
-
Design, synthesis, and biological evaluation of 3-(1-Aryl-1H-indol-5-yl)propanoic acids as new indole-based cytosolic phospholipase A2a inhibitors
-
Tomoo T, Nakatsuka T, Katayama T, Hayashi Y, Fujieda Y, Terakawa M, and Nagahira K (2014) Design, synthesis, and biological evaluation of 3-(1-Aryl-1H-indol-5-yl)propanoic acids as new indole-based cytosolic phospholipase A2a inhibitors. J Med Chem 57:7244-7262.
-
(2014)
J Med Chem
, vol.57
, pp. 7244-7262
-
-
Tomoo, T.1
Nakatsuka, T.2
Katayama, T.3
Hayashi, Y.4
Fujieda, Y.5
Terakawa, M.6
Nagahira, K.7
-
56
-
-
0029144666
-
Roles of oxidative stress in activation of Kupffer and Ito cells in liver fibrogenesis
-
Tsukamoto H, Rippe R, Niemelä O, and Lin M (1995) Roles of oxidative stress in activation of Kupffer and Ito cells in liver fibrogenesis. J Gastroenterol Hepatol 10 (Suppl 1):S50-S53.
-
(1995)
J Gastroenterol Hepatol
, vol.10
, pp. S50-S53
-
-
Tsukamoto, H.1
Rippe, R.2
Niemelä, O.3
Lin, M.4
-
57
-
-
80055028155
-
Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
-
Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, and McCullough AJ (2011) Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 54:1610-1619.
-
(2011)
Hepatology
, vol.54
, pp. 1610-1619
-
-
Zein, C.O.1
Yerian, L.M.2
Gogate, P.3
Lopez, R.4
Kirwan, J.P.5
Feldstein, A.E.6
McCullough, A.J.7
-
58
-
-
0023785310
-
Proliferation of fat-storing cells is stimulated by secretions of Kupffer cells from normal and injured liver
-
Zerbe O and Gressner AM (1988) Proliferation of fat-storing cells is stimulated by secretions of Kupffer cells from normal and injured liver. Exp Mol Pathol 49: 87-101.
-
(1988)
Exp Mol Pathol
, vol.49
, pp. 87-101
-
-
Zerbe, O.1
Gressner, A.M.2
|